Market revenue in 2023 | USD 159.8 million |
Market revenue in 2030 | USD 434.7 million |
Growth rate | 15.4% (CAGR from 2023 to 2030) |
Largest segment | Dna chips |
Fastest growing segment | Lab-on-chip |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Tissue Arrays, Cell Arrays, DNA Chips, Lab-on-chip, Protein Chips |
Key market players worldwide | Agilent Technologies Inc, PerkinElmer, Illumina Inc, Bio-Rad Laboratories Inc, Standard BioTools Inc, GE HealthCare Technologies Inc Common Stock, Thermo Fisher Scientific Inc, Qiagen NV, Randox |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biochip market will help companies and investors design strategic landscapes.
Dna chips was the largest segment with a revenue share of 38.11% in 2024. Horizon Databook has segmented the Australia biochip market based on tissue arrays, cell arrays, dna chips, lab-on-chip, protein chips covering the revenue growth of each sub-segment from 2018 to 2030.
Australia’s excellent research facilities, world-class researchers, and a firm but flexible regulatory framework have made Australia a powerhouse of pharmaceutical and biotechnology innovation. According to the data published by the Australian Trade and Investment Commission, Australia has become a hub for a thriving network of more than 470 biotechnology companies.
The significant presence of established pharmaceutical & biotechnology companies and extensive R&D initiatives being undertaken by them are expected to create high demand for biochip and genomic-based solutions in the country.
Australian Genomics, the national network of research, is engaged in creating building blocks for the smooth and complete integration of genomic medicine in routine healthcare. This network is a collaboration of 80 hospitals, laboratories that perform genetic testing, research institutes, and data management services.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia biochip market, including forecasts for subscribers. This country databook contains high-level insights into Australia biochip market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account